Bayer AG has agreed to pay $7.25 billion to settle approximately 125,000 Roundup cancer lawsuits, a proposed deal filed on February 17, 2026, in St. Louis Circuit Court. This latest settlement attempt comes after juries handed down staggering verdicts against the company — $289 million, $332 million, and $2.1 billion in individual cases — and after Bayer had already spent more than $10 billion in prior settlements and verdicts. The total financial damage from the Roundup litigation now exceeds $17 billion, making it one of the most expensive product liability sagas in corporate history.
The proposed settlement, however, is far from a done deal. It requires judicial approval from a Missouri court that has already shown early signs of pushback, and the U.S. Supreme Court is scheduled to hear oral arguments on April 27, 2026, in a related preemption case that could reshape Bayer’s entire legal exposure. Meanwhile, roughly 67,000 active claims remain outside the settlement, and claimants within it face payouts that range from as little as $10,000 to around $165,000 depending on their age, exposure history, and diagnosis. This article breaks down the major jury verdicts, the settlement’s payment structure, what claimants can realistically expect, and the legal battles still ahead.
Table of Contents
- How Did Juries Award $289M, $332M, and $2.1B Against Bayer Over Roundup Cancer Claims?
- What Does the $7.25 Billion Settlement Actually Cover — and What It Doesn’t
- How Much Will Individual Claimants Actually Receive?
- Should Claimants Accept the Settlement or Pursue Individual Litigation?
- The Supreme Court Preemption Case Could Change Everything
- How Bayer’s $63 Billion Monsanto Acquisition Became a $17 Billion Liability
- What Happens Next for Roundup Claimants and Bayer
- Conclusion
- Frequently Asked Questions
How Did Juries Award $289M, $332M, and $2.1B Against Bayer Over Roundup Cancer Claims?
The first major verdict came in August 2018, when a San Francisco jury awarded school groundskeeper Dewayne “Lee” Johnson $289 million after finding that Monsanto had acted with “malice and oppression” in failing to warn about Roundup’s cancer risks. Johnson, who was terminally ill with non-Hodgkin lymphoma, had used Roundup extensively in his work. A judge later reduced the award to $78.5 million, which Johnson accepted, and on appeal it was further cut to $20.5 million in July 2020. The gap between the jury’s outrage and the final payout tells you something important about how these cases actually resolve — juries send a message, and then the legal system whittles it down. That pattern repeated in San Diego, where a jury awarded 51-year-old Mike Dennis $332 million after finding Monsanto failed to adequately warn consumers about cancer risks.
That verdict was reduced to $28 million on appeal. Then, in March 2025, a Georgia jury delivered a $2.1 billion verdict against Bayer — one of the largest individual product liability awards in U.S. history. Across all trials, the scorecard reads 13 verdicts for Bayer and 11 for plaintiffs. Bayer wins more often than it loses at trial, but when it loses, the numbers are catastrophic. That math is precisely what drove the company to the settlement table.
What Does the $7.25 Billion Settlement Actually Cover — and What It Doesn’t
The proposed settlement, filed in Missouri’s 22nd Judicial Circuit, covers approximately 125,000 plaintiffs who have lodged claims since 2015. These are people who allege that exposure to Roundup’s active ingredient, glyphosate, caused them to develop non-Hodgkin lymphoma or related cancers. Bayer would fund the settlement through annual payments spread over up to 21 years, with caps and declining funding levels over time. That structure matters — it means claimants are not getting lump-sum payouts anytime soon, and the real value of future payments is eroded by inflation.
However, the settlement does not cover all Roundup claims. Bayer still faces roughly 67,000 active claims that fall outside this deal, and the total number of claims filed against the company stands at approximately 200,000. If you are a claimant whose case is not included in this settlement, your legal options remain open but uncertain. A supreme Court ruling in Bayer’s favor on the preemption question — whether federal EPA approval of glyphosate preempts state-law failure-to-warn claims — could dramatically reduce the value of those remaining cases. Conversely, if the Court rules against Bayer, the floodgates could open wider.
How Much Will Individual Claimants Actually Receive?
The gap between headline settlement numbers and what individual people actually receive is where the real story lives. Under the proposed $7.25 billion deal, payouts vary significantly based on the claimant’s type of exposure, age at diagnosis, and severity of illness. Agricultural workers, industrial applicators, and turf workers with long-term exposure who were diagnosed with aggressive non-Hodgkin lymphoma before age 60 can expect average payouts of roughly $165,000. That is the high end of the scale. Residential users — the homeowners who sprayed Roundup on their driveways and garden beds — who were diagnosed between ages 60 and 77 with less aggressive forms of the disease are looking at average payouts around $20,000.
Patients diagnosed at age 78 or older can expect approximately $10,000. To put this in perspective, a person who developed cancer and went through chemotherapy, radiation, or other treatment could receive less than the cost of a single month of cancer treatment in the United States. For some claimants, the settlement is meaningful. For others, particularly elderly residential users, it amounts to a nominal acknowledgment rather than real compensation. Attorney fees, typically ranging from 25 to 40 percent in contingency cases, will further reduce these amounts.
Should Claimants Accept the Settlement or Pursue Individual Litigation?
This is the practical question facing tens of thousands of people right now, and the answer depends on individual circumstances. The settlement offers certainty — a guaranteed payout, even if modest, without the risk and expense of trial. Going to trial has produced verdicts as high as $2.1 billion, but also 13 defense wins out of 24 total trials. Those are close to coin-flip odds, and even plaintiffs who win at trial have watched their awards reduced dramatically on appeal. Dewayne Johnson’s $289 million became $20.5 million. Mike Dennis’s $332 million became $28 million.
The courtroom number and the check you actually cash are very different things. On the other hand, claimants with strong cases — younger plaintiffs with aggressive cancers, clear occupational exposure, and solid medical documentation — may have legitimate reasons to opt out and pursue individual claims. The tradeoff is time, stress, and financial risk. Litigation can take years, and Bayer has shown a willingness to fight aggressively in court. The 21-year payment structure of the settlement also means that opting in does not deliver immediate financial relief. For claimants in financial distress from medical bills, neither option offers a quick solution.
The Supreme Court Preemption Case Could Change Everything
Hanging over the entire Roundup litigation is a question the Supreme Court is set to take up on April 27, 2026: does the Environmental Protection Agency’s approval of glyphosate as safe preempt state-level failure-to-warn lawsuits? If the Court rules that federal regulatory approval shields Bayer from state tort claims, it could effectively gut the remaining 67,000 active lawsuits and potentially undermine the legal basis for future Roundup claims entirely. This is a significant risk for claimants who opt out of the settlement hoping for a bigger payday through individual litigation. A favorable Supreme Court ruling for Bayer could render those cases nearly worthless overnight.
It is worth noting that the timing of Bayer’s settlement offer — just months before the Supreme Court hearing — is almost certainly strategic. The company may be offering $7.25 billion now precisely because it believes the legal landscape is about to shift in its favor. Claimants and their attorneys need to weigh this possibility carefully. A bird in the hand may be worth considerably more than a post-Supreme Court lawsuit.
How Bayer’s $63 Billion Monsanto Acquisition Became a $17 Billion Liability
When Bayer acquired Monsanto in 2018 for $63 billion, the German pharmaceutical giant believed it was buying the world’s leading agricultural biotechnology company. What it inherited was the most expensive product liability crisis in the agrochemical industry’s history. Between prior settlements exceeding $10 billion and the proposed $7.25 billion deal, Bayer’s total Roundup-related costs now surpass $17 billion — more than a quarter of the acquisition price.
The company’s stock price has reflected this reality, with shares losing significant value since the merger closed. The Monsanto acquisition is now widely regarded as one of the worst corporate deals of the past decade, a case study in due diligence failure around litigation risk. Bayer’s leadership has faced intense shareholder pressure, and the ongoing legal costs continue to weigh on the company’s ability to invest in its pharmaceutical pipeline and agricultural research.
What Happens Next for Roundup Claimants and Bayer
The immediate next steps are judicial. The St. Louis court must grant both preliminary and final approval of the $7.25 billion settlement, and early signals from the bench suggest that process will not be smooth. Missouri Lawyers Media reported in late February 2026 that the deal is already facing pushback in court, potentially over the adequacy of payouts or the treatment of certain claimant categories.
If the court rejects or significantly modifies the settlement, Bayer and plaintiffs’ attorneys will be back at the negotiating table. The Supreme Court’s April 2026 hearing adds another layer of uncertainty. Regardless of how that case is decided, the Roundup litigation has already reshaped how companies assess product liability risk in acquisitions and how regulators’ safety determinations interact with the civil justice system. For the roughly 200,000 individuals who filed claims, the path to resolution remains long and uncertain — but the $7.25 billion proposal represents the most comprehensive attempt yet to bring this decade-long legal battle toward a conclusion.
Conclusion
The Bayer Roundup settlement saga illustrates both the power and the limitations of the American civil justice system. Juries repeatedly delivered verdicts in the hundreds of millions and even billions of dollars, sending an unmistakable signal about corporate accountability. But the appeals process, settlement negotiations, and the realities of mass tort litigation mean that individual claimants — many of them cancer patients or their surviving families — will receive a fraction of those headline numbers.
Average payouts under the proposed settlement range from $10,000 to $165,000, a far cry from the jury verdicts that drove Bayer to negotiate. For claimants currently deciding whether to participate in the settlement, the key factors are the strength of their individual case, their tolerance for legal risk and delay, and the looming Supreme Court preemption decision. Those with strong occupational exposure claims and aggressive diagnoses may have reason to pursue individual litigation, while those with weaker claims or urgent financial needs may find the settlement’s certainty more appealing despite its modest payouts. Either way, the $17 billion-and-counting Roundup liability stands as a stark reminder that corporate acquisitions carry risks that no amount of due diligence can fully anticipate.
Frequently Asked Questions
Who is eligible for the $7.25 billion Roundup settlement?
The settlement covers approximately 125,000 plaintiffs who filed Roundup-related cancer claims since 2015. It primarily targets individuals diagnosed with non-Hodgkin lymphoma who used Roundup products. However, roughly 67,000 active claims remain outside the settlement.
How much money will Roundup claimants receive from the settlement?
Payouts vary significantly. Agricultural and industrial workers with long-term exposure diagnosed with aggressive NHL before age 60 may receive around $165,000 on average. Residential users diagnosed between ages 60 and 77 with less aggressive illness average about $20,000, and those diagnosed at 78 or older average roughly $10,000. Attorney fees will reduce these amounts further.
When will Roundup settlement payments be made?
Bayer has structured the settlement as annual payments over up to 21 years, with caps and declining funding levels over time. Payments cannot begin until the St. Louis Circuit Court grants both preliminary and final approval of the deal, and that process is already facing early judicial pushback.
Can I opt out of the Roundup settlement and sue Bayer individually?
Claimants generally have the right to opt out of class settlements and pursue individual litigation. However, this carries significant risk — Bayer has won 13 of 24 trials, and even large jury verdicts have been drastically reduced on appeal. Additionally, a Supreme Court ruling on federal preemption in April 2026 could reduce the value of individual claims.
How much has Bayer spent total on Roundup lawsuits?
Including prior settlements and verdicts exceeding $10 billion, plus the proposed $7.25 billion deal, Bayer’s total Roundup-related costs now surpass $17 billion. The company acquired Monsanto in 2018 for $63 billion.